砷剂治疗消化系统恶性肿瘤的临床进展  

Clinical advances:arsenic for malignancies of digestive system

作　　者：王晶晶[1] 刘伟华[1,2] 李丹[1] 谢坤霞[1] 肖延风[1] 

机构地区：[1]西安交通大学第二附属医院儿科,陕西西安710004 [2]西安市第一医院儿科,陕西西安710003

出　　处：《国外医学（医学地理分册）》2016年第1期40-43,共4页Foreign Medical Sciences：Section of Medgeography

摘　　要：近些年,砷剂在治疗晚期消化系统恶性肿瘤方面取得了一定的进展。对于进展期肝癌,三氧化二砷静脉给药联合常规TACE(经动脉化疗栓塞)或可使患者受益;对于常规化疗不再应答或(复发)的晚期结直肠癌,砷剂是一种值得探索的治疗药物;而对于难治/复发的胰腺癌,砷剂可能无效。Several clinical studies have been conducted to evaluate the efficacy and safety of arsenic for malignancies of digestive system.Patients with advanced hepatocellular carcinoma may benefit from intravenous arsenic trioxide combined with transarterial chemoembolization.More evidence is needed for refractory/relapsed colorectal carcinoma.Arsenic trioxide may not improve the outcomes of patients with refractory/relapsed pancreatic cancer.

关 键 词：砷剂 肝癌 结直肠癌 胰腺癌 

分 类 号：R591[医药卫生—内科学]